About
Molecular Glue Therapeutics
TenAces Biosciences is a biopharmaceutical company focused on the development of molecular glue therapeutics. The molecular glues are small molecules that can induce or stabilize the interaction between an E3 ligase and a target protein. This enhanced binding accelerates the tagging with ubiquitin, and subsequent removal of the target protein by the proteasome.
The company's approach, based on machine learning, 3D modeling and virtual compound screening, allows for the development of rationally designed molecular glues for a wide range of diseases.
Identity
| Name | TenAces Biosciences |
|---|---|
| Slug | tenaces-biosciences |
| Type / kind | startup |
| Source _id | 1Sa8PGtegCSYnB7Yf3D1tqKZF5vbXF9DjwsEMkJPN3SRLk0fJHfxRR |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | Rehovot |
| HQ address | Rehovot, Israel |
Web & social
| https://www.linkedin.com/company/100609564 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Artificial IntelligenceMachine LearningBiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
machine-learningpharmaceuticalscell-therapybiopharmaceutical
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}